Drugs, FDA Approval and Genotoxicity - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Drugs

FDA Approval

Genotoxicity

Trodelvy® for the Treatment of Metastatic Urothelial Cancer

The Pharma Data

APRIL 14, 2021

Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1/PD-L1 Inhibitor –. – New Indication Marks Second FDA Approval for Trodelvy in 2021 –. Premedicate with a two or three drug combination regimen (e.g., DRUG INTERACTIONS.

Genotype

Genotype Containment FDA Approval Genotoxicity

Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

The Pharma Data

APRIL 7, 2021

Food and Drug Administration (FDA) has granted full approval to Trodelvy ® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. DRUG INTERACTIONS.

HR Genotype FDA Approval Genotoxicity

Trodelvy® for the Treatment of Metastatic Urothelial Cancer

Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

Stay Connected